GLASF
Price
$6.62
Change
+$0.35 (+5.58%)
Updated
Dec 4 closing price
Capitalization
534.53M
102 days until earnings call
Intraday BUY SELL Signals
HYPMY
Price
$4.86
Change
-$0.07 (-1.42%)
Updated
Dec 4 closing price
Capitalization
3.19B
Intraday BUY SELL Signals
Interact to see
Advertisement

GLASF vs HYPMY

Header iconGLASF vs HYPMY Comparison
Open Charts GLASF vs HYPMYBanner chart's image
Glass House Brands
Price$6.62
Change+$0.35 (+5.58%)
Volume$61.04K
Capitalization534.53M
Hypera SA
Price$4.86
Change-$0.07 (-1.42%)
Volume$1.79K
Capitalization3.19B
GLASF vs HYPMY Comparison Chart in %
GLASF
Daily Signal:
Gain/Loss:
HYPMY
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
GLASF vs. HYPMY commentary
Dec 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GLASF is a Hold and HYPMY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 06, 2025
Stock price -- (GLASF: $6.62 vs. HYPMY: $4.86)
Brand notoriety: GLASF and HYPMY are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: GLASF: 35% vs. HYPMY: 17%
Market capitalization -- GLASF: $503.23M vs. HYPMY: $3.19B
GLASF [@Pharmaceuticals: Generic] is valued at $503.23M. HYPMY’s [@Pharmaceuticals: Generic] market capitalization is $3.19B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GLASF’s FA Score shows that 0 FA rating(s) are green whileHYPMY’s FA Score has 2 green FA rating(s).

  • GLASF’s FA Score: 0 green, 5 red.
  • HYPMY’s FA Score: 2 green, 3 red.
According to our system of comparison, HYPMY is a better buy in the long-term than GLASF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GLASF’s TA Score shows that 6 TA indicator(s) are bullish while HYPMY’s TA Score has 3 bullish TA indicator(s).

  • GLASF’s TA Score: 6 bullish, 3 bearish.
  • HYPMY’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, GLASF is a better buy in the short-term than HYPMY.

Price Growth

GLASF (@Pharmaceuticals: Generic) experienced а +4.58% price change this week, while HYPMY (@Pharmaceuticals: Generic) price change was -1.12% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.40%. For the same industry, the average monthly price growth was -0.87%, and the average quarterly price growth was +18.27%.

Reported Earning Dates

GLASF is expected to report earnings on Mar 18, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.40% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HYPMY($3.19B) has a higher market cap than GLASF($535M). GLASF has higher P/E ratio than HYPMY: GLASF (513.07) vs HYPMY (20.30). HYPMY YTD gains are higher at: 67.654 vs. GLASF (14.138). HYPMY has higher annual earnings (EBITDA): 1.41B vs. GLASF (49M). HYPMY has higher revenues than GLASF: HYPMY (6.66B) vs GLASF (222M).
GLASFHYPMYGLASF / HYPMY
Capitalization535M3.19B17%
EBITDA49M1.41B3%
Gain YTD14.13867.65421%
P/E Ratio513.0720.302,528%
Revenue222M6.66B3%
Total Cash40.7MN/A-
Total Debt72.8MN/A-
FUNDAMENTALS RATINGS
GLASF vs HYPMY: Fundamental Ratings
GLASF
HYPMY
OUTLOOK RATING
1..100
6178
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
10
Undervalued
PROFIT vs RISK RATING
1..100
10097
SMR RATING
1..100
9381
PRICE GROWTH RATING
1..100
6342
P/E GROWTH RATING
1..100
1005
SEASONALITY SCORE
1..100
1750

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HYPMY's Valuation (10) in the null industry is significantly better than the same rating for GLASF (93). This means that HYPMY’s stock grew significantly faster than GLASF’s over the last 12 months.

HYPMY's Profit vs Risk Rating (97) in the null industry is in the same range as GLASF (100). This means that HYPMY’s stock grew similarly to GLASF’s over the last 12 months.

HYPMY's SMR Rating (81) in the null industry is in the same range as GLASF (93). This means that HYPMY’s stock grew similarly to GLASF’s over the last 12 months.

HYPMY's Price Growth Rating (42) in the null industry is in the same range as GLASF (63). This means that HYPMY’s stock grew similarly to GLASF’s over the last 12 months.

HYPMY's P/E Growth Rating (5) in the null industry is significantly better than the same rating for GLASF (100). This means that HYPMY’s stock grew significantly faster than GLASF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GLASFHYPMY
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
62%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
61%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
62%
MACD
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
68%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
72%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 12 days ago
79%
Bullish Trend 18 days ago
67%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 2 days ago
70%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
70%
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
GLASF
Daily Signal:
Gain/Loss:
HYPMY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYEAX243.761.64
+0.68%
Rydex Energy H
SSILX15.740.10
+0.64%
State Street International Stock Sel A
IASRX23.860.06
+0.25%
Nomura Asset Strategy Fund Cl R
AWIIX16.67-0.03
-0.18%
CIBC Atlas Income Opportunities Instl
PNOYX155.05-0.36
-0.23%
Putnam Sustainable Leaders Y

GLASF and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLASF has been loosely correlated with TSNDF. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if GLASF jumps, then TSNDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLASF
1D Price
Change %
GLASF100%
+5.58%
TSNDF - GLASF
63%
Loosely correlated
-2.43%
GTBIF - GLASF
62%
Loosely correlated
+6.70%
TCNNF - GLASF
60%
Loosely correlated
+4.02%
CURLF - GLASF
57%
Loosely correlated
+9.02%
CRLBF - GLASF
57%
Loosely correlated
+6.66%
More

HYPMY and

Correlation & Price change

A.I.dvisor tells us that HYPMY and PLNH have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HYPMY and PLNH's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HYPMY
1D Price
Change %
HYPMY100%
-1.42%
PLNH - HYPMY
21%
Poorly correlated
-3.16%
CPIX - HYPMY
20%
Poorly correlated
+3.07%
GLASF - HYPMY
20%
Poorly correlated
+5.58%
KMDA - HYPMY
20%
Poorly correlated
+0.28%
JUSHF - HYPMY
18%
Poorly correlated
+1.08%
More